Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897148 | 0.87 | CYP19A1 (0.34) | — | |
| SCHEMBL2893315 | 0.86 | KDM1A (0.32) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL2889164 | 0.80 | PTGER1 (0.37) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL2888702 | 0.77 | MAPK14 (0.35) | PTGER1MRGPRX4 | |
| SCHEMBL2897305 | 0.77 | PTPN1 (0.40) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL27724254 | 0.72 | S1PR5 (0.34) | — | |
| SCHEMBL27724269 | 0.69 | S1PR5 (0.33) | PTGER1MRGPRX4 | |
| SCHEMBL2896975 | 0.68 | PTPN1 (0.50) | — | |
| SCHEMBL649118 | 0.67 | MRGPRX4 (0.33) | PTGER1PTGER4PTGER3PTGER2MRGPRX4 | |
| SCHEMBL3926598 | 0.66 | MTNR1A (0.37) | PTGER1PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-1963293-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067612-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | PTGER1 760/4885PTGER4 1365/4885PTGER3 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.